Zero Homes | $16,800,000 | (Feb 19, 2026)
Rainfall Health | $15,000,000 | (Feb 19, 2026)
inKind | $450,000,000 | (Feb 19, 2026)
Certified by Founder
Lodge
Curevo Vaccine
start up
United States
- Bothell, Washington
- 19/03/2025
- Series B
- $110,000,000
Curevo Vaccine is a clinical-stage developer of vaccines for varicella and herpes zoster. Amezosvatein (CRV-101) is an adjuvanted subunit (non-mRNA) vaccine designed to prevent herpes zoster, commonly known as shingles. Our goal with a new herpes zoster vaccine is to improve the patient experience and, ultimately, overall vaccination rates, by developing amezosvatein as a vaccine with non-inferior efficacy combined with clinically-meaningful improvements in reactogenicity when compared to Shingrix.
- Industry Biotechnology Research
- Website https://curevovaccine.com/
- LinkedIn https://www.linkedin.com/company/curevovaccine/
Related People
George SimeonFounder
United States -
Greater Seattle Area
Strategic Alliances, Global Commercialisation, M&A, Joint-Ventures, Organization Building
Balance between: Strategic Thinking - Creative Problem Solving - 'Hands-on' Execution
Avantos.ai | $25,000,000 | (Feb 19, 2026)
Korsana Biosciences | $175,000,000 | (Feb 19, 2026)
Vervesemi | $10,000,000 | (Feb 19, 2026)
DG Matrix | $60,000,000 | (Feb 19, 2026)
Synchrony Medical | $5,000,000 | (Feb 19, 2026)
Dataro | $14,280,000 | (Feb 18, 2026)
Sphinx(US) | $7,100,000 | (Feb 18, 2026)
The Compression Company | $3,400,000 | (Feb 18, 2026)
Helia Care, Inc. | $3,000,000 | (Feb 18, 2026)